Objective: We have previously found that the transcription factor peroxisome proliferator-activated receptor c (PPARc) contributes to the mechanism of action of the ketogenic diet (KD), an established treatment for pediatric refractory epilepsy. We have found that the KD increases brain PPARc and that inhibition or genetic loss of PPARc prevents the antiseizure effects of the KD on (1) acutely induced seizures in nonepileptic mice and (2) spontaneous recurrent seizures in epileptic mice. Here, we tested the hypothesis that adjuvant treatment of KD-treated mice with a PPARc agonist, pioglitazone, would result in an additive effect. Methods: Acute seizures were induced in three groups of C57Bl/6 mice by inhalation exposure to flurothyl gas. In Group 1, mice were weaned onto either a standard diet or KD comprised of a fat:carbohydrate/protein ratio of either 6:1, 3:1, or 1:1 for 2 weeks. In Group 2, vehicle or pioglitazone (0.1, 1, 10, 80 mg/kg) was administered 4 h prior to flurothyl exposure. In Group 3, vehicle or increasing doses of pioglitazone were administered to KD-treated mice 4 h prior to flurothyl exposure. Latency times to clonic seizures and generalized tonic-clonic (GTC) seizures were recorded, and isobolographic analysis was used to determine combinatorial interactions. Results: Neither KD treatment nor pioglitazone alone or in combination affected clonic seizures. However, the latency to GTC seizures was dose-dependently and significantly increased by both KD (~57%, p < 0.05) and pioglitazone (~28%, p < 0.05). Coadministration of an ineffective 1:1 KD and pioglitazone resulted in~47-55% (p < 0.05) increase in latency to GTC. Isobolographic analysis indicated a synergistic interaction of the KD and pioglitazone. Significance: These results suggest coadministration may enable reduction of the KD ratio without loss of seizure protection. Such adjuvant treatment could improve quality of life and limit adverse effects of a classic KD or high-dose pioglitazone.
The ketogenic diet (KD) is an antiseizure therapy primarily used in pediatric, refractory epilepsy. In this difficult-totreat population, many retrospective and prospective studies have consistently demonstrated that the KD is an effective treatment in about 50% of patients. 1 The classic KD consists of strict consumption of a diet of high fat and low carbohydrate/protein in a 4:1 ratio. Palatability and stringency contribute to tolerability and noncompliance in some patients. For others, a less strict 3:1 or 2:1 KD or alternative medium chain triglyceride diet, modified Atkins diet, or low glycemic index diet may provide sufficient seizure control.
understood. 3 Recently, we identified the peroxisome proliferator-activated receptor c (PPARc) as a significant contributor to the antiseizure mechanism of the KD. 4 PPARc is a nuclear transcription factor most noted as a master regulator of adipogenesis, lipid metabolism, and insulin sensitivity; however, PPARc also increases transcription of anti-inflammatory, antioxidant, and mitochondrial genes. 5 For this reason PPARc agonists, in particular the type 2 diabetes drug pioglitazone, are currently under investigation in preclinical and clinical studies for treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. 6 In our previous study, we demonstrated the antiseizure efficacy of pioglitazone in reducing spontaneous recurrent seizures in a genetic model of epilepsy. 4 Here, we hypothesized that coadministering pioglitazone with the KD would have additive effects and may allow reduction of the KD ratio without sacrificing seizure protection.
Methods

Animals
All mice were housed in the Animal Resource Facilities at Creighton University School of Medicine in a temperature (25°C) and humidity (50-60%) controlled and pathogen-free environment. Mice were given food and water ad libitum and kept on a 12-h light/dark cycle. Male and female C57Bl/6 mice were purchased from Envigo (Indianapolis, IN) and used to establish an in-house breeding colony. All procedures involving animals were in accordance with National Institutes of Health guidelines and the European Union Directive 2010/63/EU and were approved by the institutional animal care and use committee at Creighton University School of Medicine.
Dietary and pharmacological treatments
On postnatal day 21, 110 male mice were randomly assigned to one of three experimental groups. Group 1 mice were randomly weaned onto either a standard diet (SD) or one of three KD diets with ratios of 1:1, 3:1, or 6.3:1 (fat to carbohydrates plus proteins; see Table 1 for nutritional content; Bio-Serv F3666, Frenchtown, NJ, U.S.A.) for 13-18 days. Group 2 mice were weaned onto an SD for 13-29 days. On the experimental day, 4 h prior to flurothyl exposure, Group 2 mice were intraperitoneally (i.p.) injected with vehicle (1% carboxymethylcellulose in saline) or vehicle pioglitazone (0.1, 1, 10, 80 mg/kg). 7 Group 3 mice were randomly weaned onto either SD or a 1:1 KD for 12-16 days. On the experimental day, 4 h prior to flurothyl exposure, Group 3 mice were injected i.p. with vehicle (1% carboxymethylcellulose in saline) or pioglitazone (0.1, 1, 10, 80 mg/kg in 1% carboxymethylcellulose in saline).
Blood b-hydroxybutyrate and glucose measurements b-Hydroxybutyrate and glucose levels were measured prior to dietary assignment and 1 day before flurothyl testing of blood samples collected from the tail vein of each mouse using a test strip system and reader (Precision Xtra Advance Diabetes Management System with Precision Xtra blood ketone test strips and blood glucose test strips; Abbott Diabetes Care, Alameda, CA, U.S.A.) as previously performed. 4, 8, 9 Flurothyl-induced seizures All experiments were performed in a fume hood as previously described. 4 . Mice were acclimated 1 h before testing. Mice were individually placed in a 2.7-L airtight glass chamber. A 10% solution (in 95% ethanol) of flurothyl (bis-2,2,2-trifluoroethyl ether; Sigma-Aldrich, St. Louis, MO, U.S.A.) was delivered by a syringe pump (KD Scientific, Holliston, MA, U.S.A.) at a constant rate of 0.05 mL/min and allowed to drip onto a Whatman grade 1 filter paper until the mouse reached a generalized tonic-clonic (GTC) seizure with loss of posture. 10, 11 Seizure latency was measured from the first drop of flurothyl onto the filter paper to the onset of the first clonic seizure and first GTC seizure. A clonic seizure was recognized when forelimb clonus, usually bilateral but sometimes unilateral, with or without hindlimb clonus, occurred for >5 s. The number of clonic seizures • Adjuvant treatment of low ratio (1:1) KD with lowdose pioglitazone acts synergistically to increase latency to provoked GTC to a degree similar to a 6:1 KD before the GTC seizure was recorded. Once a GTC seizure developed, the mouse was promptly removed from the chamber and allowed to recover.
Isobolographic analysis
Additive, subadditive, or synergistic effects of treatment combinations were detected with isobolographic analysis methods as previously described by Grabovsky and Tallarida. 12 Briefly, simple, linear isoboles only occur for drugs with similar maximal efficacies, but for drugs with different efficacies, isoboles must be scaled accordingly. Within each treatment group, data were normalized to the peak effect and dose-response curves were generated and fit with the equation
where E is the effect, E max is the maximum effect for a specific drug, ED 50 is the dose eliciting a half-maximal effect, [agonist] is the drug dose (note: for KD ratios the numerator or fat content is used as the dose), and h is the Hill coefficient. The peak effect of pioglitazone (designated as Drug B below) was half of the peak response of the KD (designated as Drug A); therefore, for our purposes here, the effect elicited by the 6:1 KD was assumed to be the maximum response possible to which all combination effects were normalized. Using the calculated KD and pioglitazone ED 50 s and Hill coefficients, dose effects of treatment combinations in fixed ratios were simulated with the equation
where B is the dose of pioglitazone (b) after taking into account the difference in efficacies and Hill coefficients (b&prime;), B 50 is the experimentally derived ED 50 of pioglitazone (0.8315 mg/kg), EB max is the maximum effect of pioglitazone relative to the KD maximum effect (50%), EA max is the maximum effect of the KD (100%), A 50 is the experimentally derived ED 50 of KD (2.338), a is the dose of KD, and p and q are the pioglitazone and KD Hill coefficients, respectively. The isobole was constructed for treatment combinations resulting in responses 50% of the KD maximum effect and were anchored to the intercepts by the experimental observations of equieffective treatment doses alone (KD: 0, 2.338; pioglitazone: 80, 0). The isobole data points were fit with a two-phase decay equation. All graphs and fits were generated with Prism 6 software (GraphPad Software, La Jolla, CA, U.S.A.).
Reagents and statistics
Unless otherwise specified, all reagents were purchased from Sigma-Aldrich. Statistical significance was determined with Prism 6 software using a one-way or two-way analysis of variance with a Dunnett post hoc test.
Results
The ketogenic diet dose-dependently raises flurothyl-induced GTC seizure threshold
The KD has been demonstrated to have consistent effects across laboratories on seizure threshold in the flurothyl model of acutely provoked generalized clonic and tonicclonic seizures 4, 13, 14 ; thus, this model was chosen to test our hypothesis. Before performing coadministration studies, it was necessary to determine both effective and ineffective KD ratios against flurothyl-induced clonic and GTC seizures. The parameters we examined included latency to the first clonic seizure, number of clonic seizures prior to the onset of the GTC seizure, total duration in clonus prior to GTC seizure, and latency between the first clonic seizure and the GTC seizure. We observed that no matter the ratio, the KD did not affect the latency to the first clonic seizure, the number of clonic seizures, or the total duration spent in clonus ( Fig. 1A-C) . The KD did have a dose-dependent effect on the latency to the GTC seizure (Fig. 1D ). A 1:1 KD did not influence latency to GTC. However, in mice treated with a 6:1 KD, GTC was significantly increased by 57.2 AE 18.3% (16.9 AE 2 vs. 10.8 AE 1.1 min, p = 0.029). Weight, blood glucose, and b-hydroxybutyrate also demonstrated expected dose-dependent changes with increasing ratios (Fig. 2) .
Pioglitazone dose-dependently raises flurothyl-induced GTC seizure threshold Next, we determined the dose response of pioglitazone against flurothyl-induced clonic and GTC seizures. Similar to the KD, pioglitazone failed to affect the latency to the first clonic seizure, the number of clonic seizures, or the total duration spent in clonus ( Fig. 3A-C) . Pioglitazone did have a dose-dependent effect on the latency to the GTC seizure, with a peak increase of 27.5 AE 1.8% with the 80-mg/ kg dose compared to vehicle control (16 AE 0.2 vs. 12.6 AE 0.4 min, p = 0.017; Fig. 3D ).
Adjuvant treatment of 1:1 KD with pioglitazone synergistically raises flurothyl-induced GTC seizure threshold Our previous study indicated that the KD and pioglitazone share a mechanism of action via the transcription factor PPARc. 4 Therefore, we hypothesized that coadministration of a KD and pioglitazone would have additive effects. We tested this by coadministering increasing dosages of pioglitazone in a new cohort of mice treated with the ineffective 1:1 KD. We found that adjuvant treatment did not affect the latency to the first clonic seizure, the number of clonic seizures, or the total duration spent in clonus relative to SD (Fig. 4A-C) . The addition of pioglitazone had a greater than additive effect on delaying the onset of GTC seizures (Fig. 4D) . Adjuvant treatment of a 1:1 KD with a previously ineffective 0.1-mg/kg dose of pioglitazone resulted in a 46.5 AE 9.9% increase in GTC seizure latency compared to the vehicle SD mice (17.8 AE 1.2 vs. 12.2 AE 0.7 min, p = 0.044). This was similar to the mean effect of a 3:1 KD alone. Coadministration of 10 mg/kg pioglitazone with the 1:1 KD delayed GTC onset by 55.2 AE 14.7% compared to the vehicle SD mice (18.9 AE 1.8 min, p = 0.009), equivalent to the mean protection given by a 6:1 KD alone (Fig. 1D) .
To determine the type of interaction of the KD and pioglitazone, we used isobolographic analysis. The isobole provides a method to detect additive, subadditive, or synergistic effects of treatment combinations. 12 As we have observed, the KD and pioglitazone have different efficacies with pioglitazone, only achieving about 50% of the maximal response to a 6:1 KD. Therefore, we used an isobolographic method that focuses on the effect scale that accounts for the different efficacies and potencies of treatments to calculate theoretical additivity, to which experimental data were Ketogenic diet (KD) dose-dependently increased latencies to generalized tonic-clonic (GTC) seizures. (A-C) Increasing KD ratios had no effect on latency to clonic seizures (A), number of clonic seizures (B), or total duration of clonic seizures (C). (D) Latencies to GTC seizures were increased by a 3:1 KD and a 6:1 KD. Significance was determined by one-way analysis of variance followed by Dunnett multiple comparisons test, *p < 0.05 (n = 6-8 mice/group; specific numbers for each group are in the inset of the corresponding bar). SD, standard diet. Epilepsia ILAE compared. 12 We began by constructing dose-response curves for the experimental KD and pioglitazone effects and calculated the ED 50 s (2.338:1 and 0.535 mg/kg, respectively) and Hill coefficients (3.775 and 0.832, respectively; Fig. 5A,B) . Coadministration of pioglitazone with the 1:1 KD caused a 23-fold shift to the left of the pioglitazone ED 50 (0.0237 mg/kg) and decreased the Hill coefficient to 0.437 (Fig. 5B) . Using the ED 50 s and Hill coefficients from the experimental data and the method of Grabovsky and Tallarida 12 (see Methods), combinations of KD and pioglitazone in fixed ratios were simulated. Ratios favoring the KD reduced the pioglitazone ED 50 and increased Hill coefficients to near KD values, whereas ratios favoring pioglitazone shifted the curves to the right and decreased Hill coefficients (Fig. 5C) . Moreover, although pioglitazone alone has half-maximal efficacy compared to the KD, every simulated combination achieved maximal efficacy because the KD could be increased to its ED 50 even if the pioglitazone doses were unrealistically high.
Next, a theoretical dose-response curve for increasing pioglitazone doses with a fixed 1:1 KD was generated. Unlike our experimental observations (Figs. 4D and 5B), we found that the pioglitazone ED 50 only decreased to 0.283 mg/kg with a Hill coefficient of 0.638 (Fig. 5D ) and that the peak efficacy (53% of KD maximum) was similar to pioglitazone alone (Fig. 3D) . From these simulations, we were able to construct an effect scale isobole that plots the treatment dose combinations resulting in 50% of the maximum effect observed with a 6:1 KD (Fig. 5E) . Therefore, the intersection with the y-ordinate is the ED 50 of KD, whereas a high dose of pioglitazone (in this case our experimental dose, 80 mg/kg) is required to achieve the same response and is the intersection of the x-ordinate. The curvature of the isobole results from taking into account the different efficacies, potencies, and Hill coefficients. Any combination that lands on the line is additive, above the line is subadditive, and below the line is synergistic. To achieve half-maximal efficacy, we find that our simulated pioglitazone + 1:1 KD combination falls on the additivity line at 10.4 mg/kg pioglitazone, whereas the experimental data are well below the line at 0.0237 mg/kg. These data suggest that the combination of a KD and pioglitazone has synergistic effects.
Discussion
Regulation of the nuclear transcription factor PPARc contributes to the antiseizure efficacy of the KD. 4 Here, we demonstrate that the KD and the PPARc agonist pioglitazone delay the onset of flurothyl-induced GTC seizures. Moreover, we demonstrate for the first time that adjuvant treatment results in a greater than additive effect, indicating a synergistic interaction between the KD and pioglitazone.
The thiazolidinedione pioglitazone is a U.S. Food and Drug Administration (FDA)-approved drug indicated for Ketogenic diet (KD) dose-dependently increased ketone bodies and decreased glucose and weight. A 3:1 KD and a 6:1 KD significantly increased blood b-hydroxybutyrate (A), decreased blood glucose (B), and decreased body weight (C). Significance was determined by two-way analysis of variance followed by Tukey multiple comparisons test, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus within group (n = 4-8 mice/group; specific numbers for each group are in the inset of the corresponding bar). SD, standard diet. Epilepsia use in type 2 diabetes mellitus. It is a potent and highly selective agonist for the transcription factor PPARc, which regulates hundreds of genes involved in glucose and lipid metabolism, anti-inflammation, antioxidation, and mitochondrial function. PPARc is expressed in adipose tissue, skeletal muscle, liver, and brain. 5 Activation of PPARc is nutritionally regulated by natural ligands, including polyunsaturated, saturated, and oxidized fatty acids. 5 Recently, it was found that the KD increases the PPARc2 splice variant in brain of normal and epileptic mice. 4 Pioglitazone administration also increased the PPARc2 splice variant in brain. Furthermore, a PPARc antagonist or genetic loss of PPARc attenuated the antiseizure effect of the KD, and pioglitazone provided seizure protection. 4 In the current study, based on the putative shared PPARc mechanism of the KD and pioglitazone, we hypothesized that adjuvant treatment with pioglitazone may be additive and allow reduction of the KD ratio. To our surprise, the lowest ratio of KD (1:1) and lowest dose of pioglitazone (0.1 mg/kg), which alone had no effect on GTC seizures, acted synergistically when combined and provided an effect One potential explanation of synergism is direct action of either the KD or pioglitazone on other effectors simultaneous to additive action on PPARc. This could include different targets in the same or related pathways, or targets involved in brain penetration or metabolism. The greater efficacy of the KD compared to pioglitazone observed in our study supports the possibility of an "off" target mechanism. The saturated and unsaturated fatty acids provided by the KD are most likely the ligands that activate PPARc, but they may also modulate ion channels and neurotransmitter receptors important for dampening cellular hyperexcitability. 15 Also, ketone bodies generated during a KD have been implicated in the antiseizure effects of the KD via diverse mechanisms including, but not limited to, increased adenosine triphosphate (ATP) generation, inhibition of the mitochondrial membrane transition pore, opening K ATP channels, inhibiting vesicular glutamate transporters, increasing adenosine, and activating A1 receptors. 3, 9, [16] [17] [18] [19] [20] [21] However, the lack of increase of ketone bodies in mice treated with a 1:1 KD ( Fig. 2A) suggests that the actions of ketone bodies do not contribute to the synergism. Pioglitazone also has a PPARc-independent target in the mitochondrial protein mitoNEET that mediates neuroprotective effects. 22 Alternatively, crosstalk between protective pathways can result in synergism. PPARc activity is inhibited by many post-translational modifications such as ERK/MEK phosphorylation. 5 The KD has been shown to modify many of these signaling pathways; therefore, it is possible that the 1:1 KD may relieve inhibition of PPARc and prime it for activation by pioglitazone.
It could also be that KD treatment increases pioglitazone accumulation in brain by increasing penetration or decreasing metabolism. Brain penetration of pioglitazone is severely limited by P-glycoprotein. 23 Inhibition of the mammalian target of rapamycin (mTOR) reduces P-glycoprotein expression in epilepsy models, 24 and the KD inhibits mTOR 25 ; thus, although this is speculative, it is possible that the 1:1 KD reduces P-glycoprotein via inhibition of the mTOR pathway, thereby allowing more pioglitazone into the brain. 24, 25 Alternatively, both pioglitazone and KD inhibit relevant cytochrome P450s, which metabolize pioglitazone or KD biochemical constituents. Pioglitazone is metabolized by CYP2C8 and CYP3A4, 26 but currently there is no evidence that the KD regulates these enzymes. Conversely, one of the metabolic pathways of the putative biochemical effectors of the KD, acetone and polyunsaturated fatty acids, involves CYP1 and CYP2 enzymes, which are inhibited by pioglitazone [27] [28] [29] ; thus, KD constituents could increase with adjuvant treatment with pioglitazone.
The potential mechanisms of synergism become more complicated in the case of transcription factors, as the many genes under their control may be differentially regulated depending on the nature of the bound agonist (full or partial), which determines the degree of conformational change and ability of transcription factors to interact with particular corepressors and coactivators. [30] [31] [32] For example, the full agonist thiazolidinediones, including pioglitazone, exert beneficial insulin-sensitizing effects as well as detrimental side effects such as weight gain, whereas several partial agonists or so-called selective PPARc modulators have been shown to retain antidiabetic effects while eliminating weight gain via attenuated and selective gene regulatory activity in comparison to full agonists. 33, 34 The PPARc ligand binding pocket is large (130 nm 3 ), which allows structural promiscuity for a wide variety of endogenous or natural agonists (i.e., saturated and unsaturated fatty acids, eicosanoids, oxidized lipids, nitroalkenes), synthetic agonists (e.g., thiazolidinediones), and synthetic antagonists. 31, 32, 35, 36 It was recently determined that the saturated fatty acid decanoic acid, a primary constituent of the medium chain triglyceride ketogenic diet, is a ligand for PPARc at physiologically relevant concentrations. 37, 38 In vivo treatment suggests that decanoic acid is a partial agonist, as it improves glucose sensitivity and lipid profiles without weight gain in diabetic mice. 38 Other fatty acids and oxidized lipids (e.g., docosahexaenoic acid) implicated in the classic KD have likewise been found to be PPARc partial agonists. 35, 39 Functionally, cotreatment with full and partial agonists may increase expression of gene sets important for seizure control. One potentially important gene is the antioxidant catalase, which we and others have identified as upregulated by decanoic acid or the KD via PPARc 37 (personal unpublished observations). Structurally, partial and full agonists bind to different sites within the PPARc binding pocket, 35, 39 raising the possibility that cooperativity may occur between sites, thus enhancing the transcriptional activity of PPARc, similar to the interactions of partial and full agonists on ligand gated receptors. 40, 41 However, whether such an action occurs is unknown at this time. All of these possibilities pose pertinent questions worthy of future studies into the mechanisms of action of the KD and pioglitazone. Effects on longevity are also of interest, as the KD has been demonstrated to increase lifespan in a mouse model of chronic epilepsy and sudden unexpected death in epilepsy, and PPARc2 is a determinant of longevity. 8, 42 Pioglitazone reaches a peak at 4 h postadministration, and approximately 18% of the serum concentration can be found in the cerebrospinal fluid of rats. 43 Moreover, pioglitazone orally administered to mice in chow at a dose of 4 mg/kg/day (assuming consumption by a 20-g mouse of 4 g/day of 20.4 mg pioglitazone/kg chow) results in a brain concentration of 1 nM/g wet brain. 44 In the present study, 4-h pretreatment of pioglitazone dose-dependently provided seizure protection with an ED 50 of 0.5 mg/kg, indicating that the doses required to achieve an antiseizure effect most likely resulted in significant accumulation in brain tissue.
Interestingly, none of the treatments affected the characteristics of the clonic seizures. The progression from generalized clonic seizures to tonic seizures involves the propagation of seizure activity from the low-threshold forebrain circuit to the high-threshold brainstem circuit. 10, 11 This suggests that the KD and pioglitazone delay propagation to or raise the seizure threshold of the brainstem even higher in this model of acute seizures. In contrast, Araki et al. 10 found that high doses of ethosuximide, clonazepam, and diazepam greatly prolonged the latency of flurothylinduced clonic seizures in Mongolian gerbils, suggesting that these ion channel modulators increase the forebrain seizure threshold.
Previously, Bough et al. 45 found that higher KD ratios increased pentylenetetrazole seizure thresholds in rats, plateauing with a 6:1 ratio. Similarly, our study demonstrates that KD effects have a clear dependence on the fat:carbohydrate/protein ratio, with a 6:1 ratio providing the greatest increase in seizure threshold against acute flurothyl seizures. Given the unavoidable heterogeneity of patients included in human studies, it is not surprising that KD ratiodependent antiseizure efficacy is less understood. It is frequently reported that lower KD ratios are as effective as higher ratios; however, a minority of patients do experience improved seizure control when switched from a lower ratio to the classic 4:1 KD. 46 Additionally, on an individual basis, after initiating treatment with higher ratios, KD ratios can be lowered without reduction of efficacy. 46 Lower KD ratios with equivalent seizure control are preferred, as patients are more compliant (i.e., the KD is more palatable) and experience fewer or less severe adverse effects such as weight loss, delayed growth, and gastrointestinal intolerance. This is exemplified in our study, as mice on a 3:1 and 6:1 KD had minimal weight gain throughout the course of the 2-week treatment, but mice on the 1:1 KD experienced normal weight gain.
Pioglitazone dosing for monotherapy of type 2 diabetes is in the range of 15-45 mg/day. For a 100-kg adult, this translates into a dosage of 0.15-0.45 mg/kg/day, similar to the low to ED 50 doses (0.1-0.5 mg/kg) used in this study. The most common adverse events in humans at these doses include fluid retention, weight gain, edema, abdominal pain, diarrhea, and nausea. 47 Less common severe adverse effects include cardiac failure and bladder cancer, which are associated with preexisting conditions or combination with insulin and high cumulative doses of pioglitazone, respectively. 48 The potential for cardiac failure has recently earned pioglitazone a black box warning by the FDA, and it is not recommended in patients with symptomatic heart failure. Nevertheless, a phase II study in Alzheimer's disease, and its previous indication for diabetes, have demonstrated that pioglitazone is safe and well tolerated. 47 Therefore, similar to the KD, and any drug for that matter, the lowest dose that retains beneficial effects and limits adverse effects is preferred. Information on pioglitazone use in children is lacking; however, a modeling study of pioglitazone dosing for use in septic pediatric patients suggests doses of about 0.3-2 mg/kg/day inversely related to weight. 49 Recently, this estimate was used for the pioglitazone dosing rationale and successful treatment of a child with refractory nephrotic syndrome for at least 35 weeks without adverse effects attributable to pioglitazone. 50 This is an encouraging case study, but additional preclinical studies in appropriate pediatric models are needed to determine the potential safety issues of pioglitazone and KD combination treatment before larger clinical studies can be pursued.
In conclusion, the synergistic protective effects of the KD and pioglitazone in the flurothyl model of acute seizures suggest that combining pioglitazone with a KD will allow drastic reduction in the KD ratio without compromising antiseizure efficacy, thereby possibly limiting adverse effects and improving compliance and quality of life of patients and families. Future preclinical studies are required to determine the efficacy and toxicities (if any) of long-term combination treatment in models of chronic epilepsy. Hopefully, a future prospective clinical trial will enable validation of the potential repurposing of pioglitazone as adjuvant treatment with the KD for pediatric refractory epilepsy, and possibly other diseases treated with the KD.
